Ryu Kobayashi
Overview
Explore the profile of Ryu Kobayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abe E, Kobayashi R, Matsuoka R, Kanaoka T, Yamanaka S, Fujii S, et al.
CEN Case Rep
. 2025 Jan;
PMID: 39786654
A 69-year-old Japanese man developed abdominal pain, purpura, proteinuria, and hematuria while receiving treatment for pulmonary tuberculosis. A skin biopsy revealed IgA-positive leukocytoclastic vasculitis, and a renal biopsy showed IgA-positive...
2.
Ishiga K, Uehara T, Wakui H, Azushima K, Ueda E, Kanai D, et al.
Ther Apher Dial
. 2024 Dec;
PMID: 39737698
Introduction: The efficacy of lipoprotein apheresis (LA) in peripheral arterial disease (PAD) has been primarily attributed to its anti-atherosclerotic effects through the adsorption of lipoproteins. However, the other potential effects...
3.
Ishiga K, Wakui H, Azushima K, Kanaoka T, Kanai D, Kobayashi R, et al.
Intern Med
. 2024 Sep;
63(23):3157-3163.
PMID: 39343571
Objective Patients undergoing maintenance dialysis are at a higher risk of morbidity and mortality due to severe coronavirus disease 2019 (COVID-19) than the general population. However, longitudinal data regarding this...
4.
Hiura K, Suzuki C, Kubo J, Goto H, Takatori S, Ishida K, et al.
J Pharm Health Care Sci
. 2024 Sep;
10(1):57.
PMID: 39285495
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been reported to have effects beyond lowering blood glucose levels, with certain SGLT2i expanding their indications to chronic kidney disease and chronic heart failure....
5.
Kobayashi R, Kobayashi N
Front Neurol
. 2024 Sep;
15:1419405.
PMID: 39224880
Introduction: Recently, a method was developed to predict the motor Functional Independence Measure (FIM) score at discharge in patients with stroke by stratifying the effects of factors such as age...
6.
Kobayashi R, Kinugasa S, Kamano D, Sumura R, Kakiwaki H, Haze T, et al.
Ther Apher Dial
. 2024 May;
28(6):830-838.
PMID: 38783565
Introduction: Peritoneal dialysis (PD) is a mode of therapy in which the patients themselves actively participate in the care of their own disease. We examined a possible association of salt...
7.
Ishiga K, Kobayashi R, Kanaoka T, Harada J, Kato I, Fujii S, et al.
CEN Case Rep
. 2024 Apr;
13(5):416-418.
PMID: 38656748
No abstract available.
8.
Ueda E, Ishiga K, Wakui H, Kawai Y, Kobayashi R, Kinguchi S, et al.
J Atheroscler Thromb
. 2024 Apr;
31(10):1370-1385.
PMID: 38569869
Aim: Peripheral artery disease (PAD) severely impairs patient prognosis and quality of life (QOL). Although lipoprotein apheresis (LA) has been applied to patients with PAD and elevated serum atherogenic lipoproteins,...
9.
Ishiga K, Kobayashi R, Kanaoka T, Harada J, Kato I, Fujii S, et al.
CEN Case Rep
. 2024 Mar;
13(5):408-415.
PMID: 38453804
A 74-year-old Japanese male with lung squamous cell carcinoma received his first dose of immune checkpoint inhibitors (ICIs): ipilimumab and nivolumab. He developed acute kidney injury (AKI) and was admitted...
10.
Taguchi S, Azushima K, Yamaji T, Suzuki T, Abe E, Tanaka S, et al.
Hypertens Res
. 2023 Nov;
47(1):55-66.
PMID: 37957242
The progress in the research field of diabetic kidney disease (DKD) has been disturbed by the lack of reliable animal models. Angiotensin II (Ang II) type 1 receptor (AT1R)-associated protein...